Since its establishment in 1992, BioKangtai has undertaken a number of national, provincial and municipal key scientific research projects and technology development tasks, and has possessed core technologies such as polyvalent vaccines, genetic engineering vaccines and other new technology R&D and industrialization core competitiveness. The company has 8 research and development carriers such as academician expert workstations, and its products cover more than 3,130 provinces, municipalities and autonomous regions. Among them, the self-developed cell-free whitebait b-type Haemophilus influenzae combined vaccine is the domestically-innovated “quadruple vaccine”, and the 60-microg hepatitis B vaccine specifically targeting unresponsive people has the “National Key New Product” title.

30+Years

Development History

90000

Production base

30+Item

In vaccine research

400+

Research staff

8+

Available vaccine varieties

Company news Recombinant COVID-19 Vaccine (Adenovirus Vector) licensed for manufacturing
Recombinant COVID-19 Vaccine (Adenovirus Vector) licensed for manufacturing
2021-09-06

Biokangtai:RecombinantCOVID-19 Vaccine(AdenovirusVector)licensed formanufacturing,whichactively promotesvaccineexportandimproves vaccineaccessibility

More
Industry news China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
2021-02-09

China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines

More
News